BiotechTube
Home/Kyntra Bio/David DeLucia, CFA
DD

David DeLucia, CFA

Chief Financial Officer

Kyntra Bio

Therapeutic Areas

OncologyHematology

Kyntra Bio Pipeline

DrugIndicationPhase
RoxadustatAnemia in Lower-Risk Myelodysplastic Syndrome (LR-MDS)Phase 3
FG-3246Metastatic Castration-Resistant Prostate Cancer (mCRPC)Phase 2
FG-3180Metastatic Castration-Resistant Prostate Cancer (mCRPC) - ImagingPhase 2

Leadership Team at Kyntra Bio

TW
Thane Wettig
Chief Executive Officer and Director
JA
John Alden
General Counsel
JA
James A. Schoeneck
Chairman of the Board
MH
Maykin Ho, Ph.D.
Director
MG
Michael G. Kauffman, MD, PhD
Director
JL
Jeffrey L. Edwards
Director
View full Kyntra Bio profile